Kunal Lakhan
Stock Analyst at CLSA
(1.35)
# 3,473
Out of 4,429 analysts
15
Total ratings
42.9%
Success rate
-1.7%
Average return
Main Sectors:
Stocks Rated by Kunal Lakhan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NSE: EMBASSY Embassy Office Parks REIT | Maintained: Buy | ₹443.00 | $426.30 | +3.92% | 1 | Jan 5, 2026 | |
| NSE: GODREJPROP Godrej Properties Limited | Maintained: Buy | ₹2,700 → ₹2,850 | $1,798.90 | +58.43% | 2 | Oct 2, 2025 | |
| NSE: PHOENIXLTD The Phoenix Mills Limited | Upgraded: Buy | ₹1,790 | $1,871.10 | -4.33% | 1 | Jul 27, 2025 | |
| NSE: APOLLOHOSP Apollo Hospitals Enterprise Limited | Maintained: Buy | ₹8,510 | $8,469.00 | +0.48% | 1 | Jul 2, 2025 | |
| NSE: PRESTIGE Prestige Estates Projects Limited | Maintained: Buy | ₹2,380 | $1,512.50 | n/a | 1 | May 30, 2025 | |
| NSE: SOBHA Sobha Limited | Maintained: Sell | ₹1,150 | $1,417.90 | n/a | 1 | Feb 9, 2025 | |
| NSE: DLF DLF Limited | Maintained: Buy | ₹975.00 | $627.60 | n/a | 2 | Feb 6, 2025 | |
| NSE: ABBOTINDIA Abbott India Limited | Maintained: Buy | ₹30,330 | $26,065.00 | n/a | 1 | Jan 23, 2025 | |
| NSE: AUROPHARMA Aurobindo Pharma Limited | Upgraded: Buy | ₹1,400 | $1,491.90 | n/a | 1 | Jan 23, 2025 | |
| NSE: DRREDDY Dr. Reddy's Laboratories Limited | Downgraded: Sell | ₹1,090 | $1,290.70 | n/a | 1 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | ₹3,240 | $1,671.10 | n/a | 1 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | ₹1,880 | $1,862.90 | n/a | 1 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | ₹730.00 | $443.40 | n/a | 1 | Jan 23, 2025 |
Embassy Office Parks REIT
Jan 5, 2026
Maintained: Buy
Price Target: ₹443.00
Current: $426.30
Upside: +3.92%
Godrej Properties Limited
Oct 2, 2025
Maintained: Buy
Price Target: ₹2,700 → ₹2,850
Current: $1,798.90
Upside: +58.43%
The Phoenix Mills Limited
Jul 27, 2025
Upgraded: Buy
Price Target: ₹1,790
Current: $1,871.10
Upside: -4.33%
Apollo Hospitals Enterprise Limited
Jul 2, 2025
Maintained: Buy
Price Target: ₹8,510
Current: $8,469.00
Upside: +0.48%
Prestige Estates Projects Limited
May 30, 2025
Maintained: Buy
Price Target: ₹2,380
Current: $1,512.50
Upside: n/a
Sobha Limited
Feb 9, 2025
Maintained: Sell
Price Target: ₹1,150
Current: $1,417.90
Upside: n/a
DLF Limited
Feb 6, 2025
Maintained: Buy
Price Target: ₹975.00
Current: $627.60
Upside: n/a
Abbott India Limited
Jan 23, 2025
Maintained: Buy
Price Target: ₹30,330
Current: $26,065.00
Upside: n/a
Aurobindo Pharma Limited
Jan 23, 2025
Upgraded: Buy
Price Target: ₹1,400
Current: $1,491.90
Upside: n/a
Dr. Reddy's Laboratories Limited
Jan 23, 2025
Downgraded: Sell
Price Target: ₹1,090
Current: $1,290.70
Upside: n/a
Jan 23, 2025
Upgraded: Buy
Price Target: ₹3,240
Current: $1,671.10
Upside: n/a
Jan 23, 2025
Maintained: Hold
Price Target: ₹1,880
Current: $1,862.90
Upside: n/a
Jan 23, 2025
Maintained: Sell
Price Target: ₹730.00
Current: $443.40
Upside: n/a